Compare · ICCC vs OCDX
ICCC vs OCDX
Side-by-side comparison of ImmuCell Corporation (ICCC) and Ortho Clinical Diagnostics Holdings plc (OCDX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ICCC and OCDX operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- OCDX is the larger of the two at $4.08B, about 65.5x ICCC ($62.4M).
- ICCC has hit the wire 18 times in the past 4 weeks while OCDX has been quiet.
- OCDX has more recent analyst coverage (8 ratings vs 0 for ICCC).
- Company
- ImmuCell Corporation
- Ortho Clinical Diagnostics Holdings plc
- Price
- $8.39+8.96%
- $17.64+0.46%
- Market cap
- $62.4M
- $4.08B
- 1M return
- +31.50%
- -
- 1Y return
- +52.55%
- -
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1987
- 2021
- News (4w)
- 18
- 0
- Recent ratings
- 0
- 8
ImmuCell Corporation
ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. The company sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.
Ortho Clinical Diagnostics Holdings plc
Ortho Clinical Diagnostics Holdings plc engages in the vitro diagnostics business worldwide. The company offers automated instruments; and assays, reagents, and other consumables that are used by these instruments to generate test results. Its solutions include clinical chemistry and immunoassay instruments and tests to detect and monitor disease progression across a spectrum of therapeutic areas, including COVID-19 antibody and antigen tests; and immunohematology instruments and tests for blood typing to ensure patient-donor compatibility in blood transfusions, as well as donor screening instruments and tests for blood and plasma screening for infectious diseases. The company also engages in contract manufacturing activities; and provides orthocare services. Its products are used in hospitals, laboratories, clinics, blood banks, and donor centers. The company was founded in 1939 and is headquartered in Raritan, New Jersey.
Latest ICCC
- SEC Form DEF 14A filed by ImmuCell Corporation
- SEC Form 3 filed by new insider Dimarco Anthony
- SEC Form 3 filed by new insider Guillemette Gilles
- SEC Form 4 filed by Turner Kathy V
- SEC Form 4 filed by Tomsche David Scott
- SEC Form 4 filed by Basse Gloria F
- SEC Form 4 filed by Wainman Paul R
- SEC Form PRE 14A filed by ImmuCell Corporation
- SEC Form 4 filed by Gathagan Bryan K.
- SEC Form 4 filed by Wainman Paul R
Latest OCDX
- SEC Form 15-12B filed by Ortho Clinical Diagnostics Holdings plc
- SEC Form 4: Iskra Michael S. returned 150,000 units of Ordinary Shares to the company, closing all direct ownership in the company
- SEC Form 4 filed by Busky Joseph M
- SEC Form 4: Schlesinger Michael A. returned 87,637 units of Ordinary Shares to the company, closing all direct ownership in the company
- SEC Form 4 filed by Palaniappan Chockalingam
- SEC Form 4: Yates Robert Clifton returned 323,880 units of Ordinary Shares to the company, closing all direct ownership in the company
- SEC Form 4: Smith Christopher M returned 367,360 units of Ordinary Shares to the company, closing all direct ownership in the company
- SEC Form 4: Dilsaver Evelyn S returned 5,200 units of Ordinary Shares to the company, closing all direct ownership in the company
- SEC Form 4: Mac Mahon Thomas P returned 141,853 units of Ordinary Shares to the company, closing all direct ownership in the company
- SEC Form 4: Labrum Ronald K returned 109,985 units of Ordinary Shares to the company, closing all direct ownership in the company